Millennium Management LLC Trims Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Millennium Management LLC lowered its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 71.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 22,196 shares of the biopharmaceutical company's stock after selling 55,734 shares during the period. Millennium Management LLC's holdings in Agios Pharmaceuticals were worth $729,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Envestnet Asset Management Inc. lifted its holdings in shares of Agios Pharmaceuticals by 3.3% in the fourth quarter. Envestnet Asset Management Inc. now owns 24,805 shares of the biopharmaceutical company's stock valued at $815,000 after purchasing an additional 795 shares in the last quarter. Venturi Wealth Management LLC bought a new position in shares of Agios Pharmaceuticals in the fourth quarter valued at approximately $33,000. Vanguard Group Inc. lifted its holdings in shares of Agios Pharmaceuticals by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 5,631,321 shares of the biopharmaceutical company's stock valued at $185,045,000 after purchasing an additional 85,339 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of Agios Pharmaceuticals by 0.9% in the fourth quarter. Northern Trust Corp now owns 595,480 shares of the biopharmaceutical company's stock valued at $19,567,000 after purchasing an additional 5,372 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Agios Pharmaceuticals by 48.8% in the fourth quarter. Bank of New York Mellon Corp now owns 265,514 shares of the biopharmaceutical company's stock valued at $8,725,000 after purchasing an additional 87,089 shares in the last quarter.

Agios Pharmaceuticals Stock Up 2.2%

Agios Pharmaceuticals stock traded up $0.75 during mid-day trading on Friday, reaching $34.33. 376,484 shares of the company's stock were exchanged, compared to its average volume of 667,518. The business's fifty day simple moving average is $28.98 and its 200 day simple moving average is $34.38. The firm has a market capitalization of $1.99 billion, a PE ratio of 3.03 and a beta of 0.73. Agios Pharmaceuticals, Inc. has a one year low of $23.42 and a one year high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) EPS for the quarter, topping analysts' consensus estimates of ($1.80) by $0.25. The business had revenue of $8.73 million for the quarter, compared to analyst estimates of $9.86 million. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. On average, sell-side analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, Director Jacqualyn A. Fouse sold 7,497 shares of the firm's stock in a transaction on Thursday, April 10th. The stock was sold at an average price of $25.90, for a total value of $194,172.30. Following the completion of the sale, the director now directly owns 149,220 shares of the company's stock, valued at $3,864,798. This trade represents a 4.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Company insiders own 4.30% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on AGIO shares. Wall Street Zen lowered Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Monday, May 19th. Scotiabank dropped their target price on Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating on the stock in a report on Friday, May 2nd. Finally, HC Wainwright started coverage on Agios Pharmaceuticals in a report on Monday, February 24th. They issued a "buy" rating and a $58.00 target price on the stock. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $56.50.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.